{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:14:22Z","timestamp":1793402062322,"version":"4.5.0"},"reference-count":287,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2019-01066"],"award-info":[{"award-number":["2019-01066"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2022-00562"],"award-info":[{"award-number":["2022-00562"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.phrs.2024.107431","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T15:56:31Z","timestamp":1726847791000},"page":"107431","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Recent developments of topoisomerase inhibitors: Clinical trials, emerging indications, novel molecules and global sales"],"prefix":"10.1016","volume":"209","author":[{"given":"Andrey D.","family":"Bondarev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rgen","family":"Jonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir N.","family":"Chubarev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim V.","family":"Tarasov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Alejandro","family":"Lagunas-Rangel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helgi B.","family":"Schi\u00f6th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.phrs.2024.107431_bib1","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1111\/febs.13307","article-title":"DNA structure and function","volume":"282","author":"Travers","year":"2015","journal-title":"FEBS J."},{"key":"10.1016\/j.phrs.2024.107431_bib2","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.plrev.2016.05.001","article-title":"Disentangling DNA molecules","volume":"18","author":"Vologodskii","year":"2016","journal-title":"Phys. Life Rev."},{"key":"10.1016\/j.phrs.2024.107431_bib3","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev.bi.65.070196.003223","article-title":"DNA topoisomerases","volume":"65","author":"Wang","year":"1996","journal-title":"Annu Rev. Biochem"},{"key":"10.1016\/j.phrs.2024.107431_bib4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1146\/annurev.pharmtox.41.1.53","article-title":"Tumor cell death induced by topoisomerase-targeting drugs","volume":"41","author":"Li","year":"2001","journal-title":"Annu Rev. Pharm. Toxicol."},{"issue":"8","key":"10.1016\/j.phrs.2024.107431_bib5","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1517\/13543776.2013.790958","article-title":"Topoisomerase inhibitors as anticancer agents: a patent update","volume":"23","author":"Khadka","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.phrs.2024.107431_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112326","article-title":"Recent advances in DNA gyrase-targeted antimicrobial agents","volume":"199","author":"Dighe","year":"2020","journal-title":"Eur. J. Med Chem."},{"key":"10.1016\/j.phrs.2024.107431_bib7","doi-asserted-by":"crossref","unstructured":"World Health Organization Model List of Essential Medicines \u2013 22nd List, 2021 Geneva , World Health Organization , 2021, Model List of Essential Medicines \u2013 22nd ListWorld Health Organization, 2021.","DOI":"10.1530\/ey.19.13.1"},{"issue":"8","key":"10.1016\/j.phrs.2024.107431_bib8","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrd3478","article-title":"Trends in the exploitation of novel drug targets","volume":"10","author":"Rask-Andersen","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2024.107431_bib9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1146\/annurev-pharmtox-011613-135943","article-title":"The druggable genome: evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication","volume":"54","author":"Rask-Andersen","year":"2014","journal-title":"Annu Rev. Pharm."},{"issue":"6","key":"10.1016\/j.phrs.2024.107431_bib10","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.tips.2018.03.003","article-title":"Orphan Drugs and Their Impact on Pharmaceutical Development [published correction appears in Trends Pharmacol Sci. 2018 Dec;39(12):1077]","volume":"39","author":"Attwood","year":"2018","journal-title":"Trends Pharm. Sci."},{"issue":"7","key":"10.1016\/j.phrs.2024.107431_bib11","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1080\/15476286.2017.1330741","article-title":"Type IA topoisomerases can be \"magicians\" for both DNA and RNA in all domains of life","volume":"14","author":"Ahmad","year":"2017","journal-title":"RNA Biol."},{"key":"10.1016\/j.phrs.2024.107431_bib12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev.biochem.70.1.369","article-title":"DNA topoisomerases: structure, function, and mechanism","volume":"70","author":"Champoux","year":"2001","journal-title":"Annu Rev. Biochem"},{"issue":"6459","key":"10.1016\/j.phrs.2024.107431_bib13","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/367138a0","article-title":"Three-dimensional structure of the 67K N-terminal fragment of E. coli DNA topoisomerase I","volume":"367","author":"Lima","year":"1994","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.phrs.2024.107431_bib14","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0969-2126(00)80027-1","article-title":"The structure of Escherichia coli DNA topoisomerase III","volume":"7","author":"Mondrag\u00f3n","year":"1999","journal-title":"Structure"},{"issue":"11","key":"10.1016\/j.phrs.2024.107431_bib15","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1073\/pnas.73.11.3872","article-title":"DNA gyrase: an enzyme that introduces superhelical turns into DNA","volume":"73","author":"Gellert","year":"1976","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.phrs.2024.107431_bib16","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0092-8674(90)90172-B","article-title":"New topoisomerase essential for chromosome segregation in E. coli [published correction appears in Cell 1991 Jun 28;65(7):1289]","volume":"63","author":"Kato","year":"1990","journal-title":"Cell"},{"issue":"1-3","key":"10.1016\/j.phrs.2024.107431_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0167-4781(98)00126-2","article-title":"DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities","volume":"1400","author":"Levine","year":"1998","journal-title":"Biochim Biophys. Acta"},{"issue":"13","key":"10.1016\/j.phrs.2024.107431_bib18","doi-asserted-by":"crossref","first-page":"7593","DOI":"10.1074\/jbc.271.13.7593","article-title":"Biochemical and biophysical analyses of recombinant forms of human topoisomerase I","volume":"271","author":"Stewart","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.phrs.2024.107431_bib19","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1002\/j.1460-2075.1986.tb04504.x","article-title":"The nucleotide sequence of the fission yeast DNA topoisomerase II gene: structural and functional relationships to other DNA topoisomerases","volume":"5","author":"Uemura","year":"1986","journal-title":"EMBO J."},{"issue":"2","key":"10.1016\/j.phrs.2024.107431_bib20","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/0092-8674(89)90855-6","article-title":"A hyper-recombination mutation in S. cerevisiae identifies a novel eukaryotic topoisomerase","volume":"58","author":"Wallis","year":"1989","journal-title":"Cell"},{"issue":"34","key":"10.1016\/j.phrs.2024.107431_bib21","doi-asserted-by":"crossref","first-page":"16739","DOI":"10.1016\/S0021-9258(18)49317-9","article-title":"Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme","volume":"262","author":"Drake","year":"1987","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.phrs.2024.107431_bib22","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1073\/pnas.93.8.3653","article-title":"Human TOP3: a single-copy gene encoding DNA topoisomerase III","volume":"93","author":"Hanai","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.phrs.2024.107431_bib23","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/nar\/27.4.993","article-title":"A new human topoisomerase III that interacts with SGS1 protein","volume":"27","author":"Ng","year":"1999","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.virol.2007.02.037","article-title":"Variola virus topoisomerase: DNA cleavage specificity and distribution of sites in Poxvirus genomes","volume":"365","author":"Minkah","year":"2007","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.phrs.2024.107431_bib25","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/0042-6822(92)90558-7","article-title":"A gene homologous to topoisomerase II in African swine fever virus","volume":"188","author":"Garc\u00eda-Beato","year":"1992","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1017\/S003358350800468X","article-title":"DNA topoisomerases: harnessing and constraining energy to govern chromosome topology","volume":"41","author":"Schoeffler","year":"2008","journal-title":"Q Rev. Biophys."},{"issue":"9","key":"10.1016\/j.phrs.2024.107431_bib27","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/nn.3479","article-title":"Top3\u03b2 is an RNA topoisomerase that works with fragile X syndrome protein to promote synapse formation","volume":"16","author":"Xu","year":"2013","journal-title":"Nat. Neurosci."},{"issue":"19","key":"10.1016\/j.phrs.2024.107431_bib28","doi-asserted-by":"crossref","first-page":"12114","DOI":"10.1073\/pnas.192449499","article-title":"Dual localization of human DNA topoisomerase IIIalpha to mitochondria and nucleus","volume":"99","author":"Wang","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"19","key":"10.1016\/j.phrs.2024.107431_bib29","doi-asserted-by":"crossref","first-page":"10608","DOI":"10.1073\/pnas.191321998","article-title":"Human mitochondrial topoisomerase I","volume":"98","author":"Zhang","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"Pt 9","key":"10.1016\/j.phrs.2024.107431_bib30","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1099\/13500872-140-9-2371","article-title":"Immunogold localization of GyrA and GyrB proteins in Escherichia coli","volume":"140","author":"Thornton","year":"1994","journal-title":"Microbiology"},{"issue":"8","key":"10.1016\/j.phrs.2024.107431_bib31","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1128\/JB.188.8.3002-3011.2006","article-title":"Differential and dynamic localization of topoisomerases in Bacillus subtilis","volume":"188","author":"Tadesse","year":"2006","journal-title":"J. Bacteriol."},{"issue":"36","key":"10.1016\/j.phrs.2024.107431_bib32","doi-asserted-by":"crossref","first-page":"25676","DOI":"10.1016\/S0021-9258(18)35660-6","article-title":"Purification and characterization of DNA topoisomerase IV in Escherichia coli","volume":"267","author":"Kato","year":"1992","journal-title":"J. Biol. Chem."},{"issue":"6220","key":"10.1016\/j.phrs.2024.107431_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.phrs.2024.107431_bib34","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1161\/CIRCRESAHA.108.183905","article-title":"Cdc2-like kinases and DNA topoisomerase I regulate alternative splicing of tissue factor in human endothelial cells","volume":"104","author":"Eisenreich","year":"2009","journal-title":"Circ. Res"},{"issue":"2","key":"10.1016\/j.phrs.2024.107431_bib35","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0167-4781(96)00063-2","article-title":"Analysis of foetal expression sites of human type II DNA topoisomerase alpha and beta mRNAs by in situ hybridisation","volume":"1307","author":"Zandvliet","year":"1996","journal-title":"Biochim Biophys. Acta"},{"issue":"9","key":"10.1016\/j.phrs.2024.107431_bib36","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/bjc.1997.227","article-title":"The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues","volume":"75","author":"Turley","year":"1997","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib37","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0167-4781(92)90050-A","article-title":"Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development","volume":"1132","author":"Capranico","year":"1992","journal-title":"Biochim Biophys. Acta"},{"issue":"6","key":"10.1016\/j.phrs.2024.107431_bib38","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/nrm831","article-title":"Cellular roles of DNA topoisomerases: a molecular perspective","volume":"3","author":"Wang","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"6","key":"10.1016\/j.phrs.2024.107431_bib39","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41580-022-00452-3","article-title":"Human topoisomerases and their roles in genome stability and organization","volume":"23","author":"Pommier","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1-3","key":"10.1016\/j.phrs.2024.107431_bib40","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0167-4781(98)00128-6","article-title":"Investigating the biological functions of DNA topoisomerases in eukaryotic cells","volume":"1400","author":"Nitiss","year":"1998","journal-title":"Biochim Biophys. Acta"},{"issue":"6","key":"10.1016\/j.phrs.2024.107431_bib41","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.biocel.2012.03.005","article-title":"DNA topoisomerase II\u03b2: a player in regulation of gene expression and cell differentiation","volume":"44","author":"V\u00e1vrov\u00e1","year":"2012","journal-title":"Int J. Biochem Cell Biol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib42","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.molcel.2017.11.033","article-title":"Topoisomerase 3\u03b1 Is Required for Decatenation and Segregation of Human mtDNA","volume":"69","author":"Nicholls","year":"2018","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib43","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1038\/s41467-020-16884-4","article-title":"Topoisomerase 3\u03b2 knockout mice show transcriptional and behavioural impairments associated with neurogenesis and synaptic plasticity","volume":"11","author":"Joo","year":"2020","journal-title":"Nat. Commun."},{"issue":"17","key":"10.1016\/j.phrs.2024.107431_bib44","doi-asserted-by":"crossref","first-page":"9766","DOI":"10.1073\/pnas.171579898","article-title":"Type I topoisomerase activity is required for proper chromosomal segregation in Escherichia coli","volume":"98","author":"Zhu","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.phrs.2024.107431_bib45","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1093\/nar\/gkab270","article-title":"What makes a type IIA topoisomerase a gyrase or a Topo IV?","volume":"49","author":"Hirsch","year":"2021","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"10.1016\/j.phrs.2024.107431_bib46","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.ijrobp.2006.02.045","article-title":"Topoisomerase II alpha expression correlates with diminished disease-free survival in invasive breast cancer","volume":"65","author":"O'Connor","year":"2006","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"issue":"10","key":"10.1016\/j.phrs.2024.107431_bib47","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1007\/s10620-017-4718-4","article-title":"Overexpression of topoisomerase 2-alpha confers a poor prognosis in pancreatic adenocarcinoma identified by co-expression analysis","volume":"62","author":"Zhou","year":"2017","journal-title":"Dig. Dis. Sci."},{"issue":"2","key":"10.1016\/j.phrs.2024.107431_bib48","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1080\/21655979.2021.2023985","article-title":"DNA topoisomerase II alpha promotes the metastatic characteristics of glioma cells by transcriptionally activating \u03b2-catenin","volume":"13","author":"Liu","year":"2022","journal-title":"Bioengineered"},{"issue":"3","key":"10.1016\/j.phrs.2024.107431_bib49","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.gpb.2016.02.004","article-title":"Topoisomerase I in human disease pathogenesis and treatments","volume":"14","author":"Li","year":"2016","journal-title":"Genom. Proteom. Bioinforma."},{"issue":"3","key":"10.1016\/j.phrs.2024.107431_bib50","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/nar\/gkn936","article-title":"Bacterial topoisomerase I as a target for discovery of antibacterial compounds","volume":"37","author":"Tse-Dinh","year":"2009","journal-title":"Nucleic Acids Res"},{"issue":"20","key":"10.1016\/j.phrs.2024.107431_bib51","doi-asserted-by":"crossref","first-page":"11291","DOI":"10.1073\/pnas.1534874100","article-title":"Poxvirus DNA topoisomerase knockout mutant exhibits decreased infectivity associated with reduced early transcription","volume":"100","author":"Da Fonseca","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2024.107431_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104874","article-title":"Topoisomerase III-\u03b2 is required for efficient replication of positive-sense RNA viruses","volume":"182","author":"Prasanth","year":"2020","journal-title":"Antivir. Res"},{"issue":"12","key":"10.1016\/j.phrs.2024.107431_bib53","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.190222","article-title":"Loss of TOP3B leads to increased R-loop formation and genome instability","volume":"9","author":"Zhang","year":"2019","journal-title":"Open Biol."},{"issue":"5","key":"10.1016\/j.phrs.2024.107431_bib54","first-page":"2704","article-title":"Topoisomerase 3\u03b2 is the major topoisomerase for mRNAs and linked to neurodevelopment and mental dysfunction","volume":"45","author":"Ahmad","year":"2017","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"10.1016\/j.phrs.2024.107431_bib55","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ajhg.2018.07.001","article-title":"Mutations in TOP3A Cause a Bloom Syndrome-like Disorder [published correction appears in Am J Hum Genet. 2018 Sep 6;103(3):456] [published correction appears in Am J Hum Genet. 2024 May 2;111(5):996]","volume":"103","author":"Martin","year":"2018","journal-title":"Am. J. Hum. Genet"},{"key":"10.1016\/j.phrs.2024.107431_bib56","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejmech.2019.03.034","article-title":"A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade","volume":"171","author":"Liang","year":"2019","journal-title":"Eur. J. Med Chem."},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib57","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1080\/14756366.2020.1821676","article-title":"DNA topoisomerases as molecular targets for anticancer drugs","volume":"35","author":"Buzun","year":"2020","journal-title":"J. Enzym. Inhib. Med Chem."},{"key":"10.1016\/j.phrs.2024.107431_bib58","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1146\/annurev.bi.58.070189.002031","article-title":"DNA topoisomerase poisons as antitumor drugs","volume":"58","author":"Liu","year":"1989","journal-title":"Annu Rev. Biochem"},{"issue":"9","key":"10.1016\/j.phrs.2024.107431_bib59","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0165-6147(97)01095-X","article-title":"A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons","volume":"18","author":"Capranico","year":"1997","journal-title":"Trends Pharm. Sci."},{"issue":"D1","key":"10.1016\/j.phrs.2024.107431_bib60","doi-asserted-by":"crossref","first-page":"D523","DOI":"10.1093\/nar\/gkac1052","article-title":"UniProt: the universal protein knowledgebase in 2023","volume":"51","author":"UniProt Consortium","year":"2023","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10.1016\/j.phrs.2024.107431_bib61","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/bioinformatics\/bty633","article-title":"ape 5.0: an environment for modern phylogenetics and evolutionary analyses in R","volume":"35","author":"Paradis","year":"2019","journal-title":"Bioinformatics"},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib62","doi-asserted-by":"crossref","DOI":"10.1002\/cpbi.96","article-title":"Using ggtree to visualize data on tree-like structures","volume":"69","author":"Yu","year":"2020","journal-title":"Curr. Protoc. Bioinforma."},{"key":"10.1016\/j.phrs.2024.107431_bib63","unstructured":"Center Watch. Clinical Research and Drug Information. Available at: \u3008https:\/\/www.centerwatch.com\/\u3009, 2018 (Last accessed March 2, 2018)."},{"issue":"D1","key":"10.1016\/j.phrs.2024.107431_bib64","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.phrs.2024.107431_bib65","unstructured":"US Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. Available at: \u3008https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm\u3009, 2024 (Last accessed May 3, 2024)."},{"key":"10.1016\/j.phrs.2024.107431_bib66","unstructured":"European Medicines Agency. EMA Medicines database. Available at: \u3008https:\/\/www.ema.europa.eu\/en\/medicines\u3009, 2024 (Last accessed April 25, 2024)."},{"key":"10.1016\/j.phrs.2024.107431_bib67","unstructured":"National Institute for Health and Care Excellence. NICE Guidance and Advice list. Available at: \u3008https:\/\/www.nice.org.uk\/guidance\/published?ngt=Technology%20appraisal%20guidance&ndt=Guidance\u3009, 2024 (Last accessed May 22, 2024)."},{"issue":"D1","key":"10.1016\/j.phrs.2024.107431_bib68","doi-asserted-by":"crossref","first-page":"D1438","DOI":"10.1093\/nar\/gkad944","article-title":"The IUPHAR\/BPS Guide to PHARMACOLOGY in 2024","volume":"52","author":"Harding","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.phrs.2024.107431_bib69","unstructured":"The National Institute of Health. Clinical Trials database. Available at: \u3008https:\/\/clinicaltrials.gov\u3009, 2024 (Last accessed April 13, 2024)."},{"key":"10.1016\/j.phrs.2024.107431_bib70","unstructured":"European Medicines Agency. EU Clinical Trials Register. Available at: \u3008https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search\u3009, 2024 (Last accessed April 13, 2024)."},{"key":"10.1016\/j.phrs.2024.107431_bib71","unstructured":"National Health and Medical Research Council. The Australian New Zealand Clinical Trials Registry. Available at: \u3008https:\/\/www.anzctr.org.au\/TrialSearch.aspx\u3009, 2024 (Last accessed April 13, 2024)."},{"issue":"5","key":"10.1016\/j.phrs.2024.107431_bib72","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.chembiol.2010.04.012","article-title":"DNA topoisomerases and their poisoning by anticancer and antibacterial drugs","volume":"17","author":"Pommier","year":"2010","journal-title":"Chem. Biol."},{"issue":"2","key":"10.1016\/j.phrs.2024.107431_bib73","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1042\/BCJ20160583","article-title":"Topoisomerases as anticancer targets","volume":"475","author":"Delgado","year":"2018","journal-title":"Biochem J."},{"issue":"22","key":"10.1016\/j.phrs.2024.107431_bib74","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1158\/1078-0432.CCR-19-1089","article-title":"Targeting topoisomerase I in the era of precision medicine","volume":"25","author":"Thomas","year":"2019","journal-title":"Clin. Cancer Res"},{"issue":"3","key":"10.1016\/j.phrs.2024.107431_bib75","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1021\/acs.jmedchem.9b00726","article-title":"Dual inhibitors of human DNA topoisomerase II and Other Cancer-Related Targets","volume":"63","author":"Skok","year":"2020","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2024.107431_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104551","article-title":"Topoisomerase inhibitors: pharmacology and emerging nanoscale delivery systems","volume":"151","author":"Dehshahri","year":"2020","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2024.107431_bib77","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.biopha.2018.04.021","article-title":"DNA gyrase inhibitors: progress and synthesis of potent compounds as antibacterial agents","volume":"103","author":"Khan","year":"2018","journal-title":"Biomed. Pharm."},{"issue":"8","key":"10.1016\/j.phrs.2024.107431_bib78","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.3390\/pharmaceutics13081289","article-title":"Structural characterization of the millennial antibacterial (fluoro)quinolones-shaping the fifth generation","volume":"13","author":"Rusu","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib79","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1021\/id500013t","article-title":"A new-class antibacterial-almost. lessons in drug discovery and development: a critical analysis of more than 50 years of effort toward ATPase inhibitors of DNA gyrase and topoisomerase IV","volume":"1","author":"Bisacchi","year":"2015","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.phrs.2024.107431_bib80","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ejmech.2018.04.059","article-title":"New developments in non-quinolone-based antibiotics for the inhibiton of bacterial gyrase and topoisomerase IV","volume":"152","author":"Badshah","year":"2018","journal-title":"Eur. J. Med Chem."},{"issue":"12","key":"10.1016\/j.phrs.2024.107431_bib81","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1111\/bcp.14889","article-title":"Recent developments of HDAC inhibitors: emerging indications and novel molecules","volume":"87","author":"Bondarev","year":"2021","journal-title":"Br. J. Clin. Pharm."},{"issue":"11","key":"10.1016\/j.phrs.2024.107431_bib82","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: targets, indications and inhibitor design [published correction appears in Nat Rev Drug Discov. 2021 Oct;20(10):798]","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2024.107431_bib83","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1057083","article-title":"Recent developments of phosphodiesterase inhibitors: clinical trials, emerging indications and novel molecules","volume":"13","author":"Bondarev","year":"2022","journal-title":"Front Pharm."},{"issue":"D1","key":"10.1016\/j.phrs.2024.107431_bib84","doi-asserted-by":"crossref","first-page":"D1265","DOI":"10.1093\/nar\/gkad976","article-title":"DrugBank 6.0: the DrugBank Knowledgebase for 2024","volume":"52","author":"Knox","year":"2024","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"10.1016\/j.phrs.2024.107431_bib85","doi-asserted-by":"crossref","first-page":"D1307","DOI":"10.1093\/nar\/gkab918","article-title":"NCATS Inxight Drugs: a comprehensive and curated portal for translational research","volume":"50","author":"Siramshetty","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.phrs.2024.107431_bib86","unstructured":"AdisInsight International. AdisInsight database. Available at: \u3008https:\/\/adisinsight.springer.com\u3009. (Last accessed April 15, 2024)."},{"issue":"10","key":"10.1016\/j.phrs.2024.107431_bib87","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1039\/C9MD00120D","article-title":"Quinolone antibiotics","volume":"10","author":"Pham","year":"2019","journal-title":"Medchemcomm"},{"issue":"4","key":"10.1016\/j.phrs.2024.107431_bib88","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1128\/AAC.50.4.1136-1142.2006","article-title":"Structure-activity relationships of aminocoumarin-type gyrase and topoisomerase IV inhibitors obtained by combinatorial biosynthesis","volume":"50","author":"Flatman","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.phrs.2024.107431_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117381","article-title":"Synthesis of novobiocin derivatives and evaluation of their antigonococcal activity and pharmacokinetics","volume":"92","author":"Sasaki","year":"2023","journal-title":"Bioorg. Med Chem."},{"issue":"D1","key":"10.1016\/j.phrs.2024.107431_bib90","doi-asserted-by":"crossref","first-page":"D1373","DOI":"10.1093\/nar\/gkac956","article-title":"PubChem 2023 update","volume":"51","author":"Kim","year":"2023","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"10.1016\/j.phrs.2024.107431_bib91","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0006-2952(01)00522-6","article-title":"Role of the sugar moiety in the pharmacological activity of anthracyclines: development of a novel series of disaccharide analogs","volume":"61","author":"Zunino","year":"2001","journal-title":"Biochem Pharm."},{"issue":"Suppl","key":"10.1016\/j.phrs.2024.107431_bib92","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1007\/BF00684860","article-title":"Structure-activity relationships of VP-16 analogues","volume":"34","author":"Long","year":"1994","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.phrs.2024.107431_bib93","series-title":"Natural Products","article-title":"Chemistry and Biology of Camptothecin and its Derivatives","author":"Kacprzak","year":"2013"},{"issue":"12","key":"10.1016\/j.phrs.2024.107431_bib94","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1021\/jm501881c","article-title":"Origins of the quinolone class of antibacterials: an expanded \"discovery story\"","volume":"58","author":"Bisacchi","year":"2015","journal-title":"J. Med Chem."},{"issue":"5","key":"10.1016\/j.phrs.2024.107431_bib95","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0025-7125(16)32600-1","article-title":"Nalidixic acid in acute and chronic urinary tract infections","volume":"54","author":"Zinsser","year":"1970","journal-title":"Med Clin. North Am."},{"issue":"3","key":"10.1016\/j.phrs.2024.107431_bib96","doi-asserted-by":"crossref","DOI":"10.1099\/jmm.0.001458","article-title":"Invasion and diversity in Pseudomonas aeruginosa urinary tract infections","volume":"71","author":"Newman","year":"2022","journal-title":"J. Med Microbiol"},{"issue":"Suppl T1","key":"10.1016\/j.phrs.2024.107431_bib97","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/oxfordjournals.jac.a020889","article-title":"Quinolone generations: natural history or natural selection","volume":"46","author":"Ball","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"issue":"5","key":"10.1016\/j.phrs.2024.107431_bib98","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1128\/AAC.18.5.738","article-title":"In vitro antimicrobial activity of rosoxacin against Neisseria gonorrhoeae, Chlamydia trachomatis, and Ureaplasma urealyticum","volume":"18","author":"Dobson","year":"1980","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"10.1016\/j.phrs.2024.107431_bib99","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1128\/AAC.25.4.455","article-title":"Rosoxacin in the therapy of uncomplicated gonorrhea","volume":"25","author":"Romanowski","year":"1984","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.phrs.2024.107431_bib100","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1128\/AAC.8.2.132","article-title":"Pipemidic acid, a new antibacterial agent active against Pseudomonas aeruginosa: in vitro properties","volume":"8","author":"Shimizu","year":"1975","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.phrs.2024.107431_bib101","first-page":"123","article-title":"Utilization, spending, and price trends for quinolones in the US medicaid programs: 25 years' experience 1991-2015","volume":"1","author":"Almalki","year":"2017","journal-title":"Pharm. Open"},{"issue":"12 Suppl 2","key":"10.1016\/j.phrs.2024.107431_bib102","doi-asserted-by":"crossref","first-page":"ii37","DOI":"10.1093\/jac\/dkab176","article-title":"Consumption of quinolones in the community, European Union\/European Economic Area, 1997-2017","volume":"76","author":"Adriaenssens","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"issue":"9","key":"10.1016\/j.phrs.2024.107431_bib103","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/acem.14545","article-title":"High prevalence of fluoroquinolone-resistant UTI among US emergency department patients diagnosed with urinary tract infection, 2018-2020","volume":"29","author":"Faine","year":"2022","journal-title":"Acad. Emerg. Med"},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib104","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12879-021-05931-0","article-title":"Euro-GASP Network. Associations between antimicrobial susceptibility\/resistance of Neisseria gonorrhoeae isolates in European Union\/European Economic Area and patients' gender, sexual orientation and anatomical site of infection, 2009-2016","volume":"21","author":"Jacobsson","year":"2021","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.phrs.2024.107431_bib105","unstructured":"U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. Available at: \u3008https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-updates-warnings-oral-and-injectable-fluoroquinolone-antibiotics\u3009."},{"key":"10.1016\/j.phrs.2024.107431_bib106","unstructured":"European Medicines Agency. Quinolone- and fluoroquinolone-containing medicinal products \u2013 referral. Available at: \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/quinolone-fluoroquinolone-containing-medicinal-products#related-medicines\u3009."},{"key":"10.1016\/j.phrs.2024.107431_bib107","unstructured":"U.S. Food and Drug Administration. FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. Available at: \u3008https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-increased-risk-ruptures-or-tears-aorta-blood-vessel-fluoroquinolone-antibiotics\u3009."},{"key":"10.1016\/j.phrs.2024.107431_bib108","unstructured":"US Food and Drug Administration. FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes. Available at: \u3008https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-reinforces-safety-information-about-serious-low-blood-sugar-levels-and-mental-health-side\u3009."},{"key":"10.1016\/j.phrs.2024.107431_bib109","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.2147\/DDDT.S229882","article-title":"Levonadifloxacin, a novel broad-spectrum anti-MRSA benzoquinolizine quinolone agent: review of current evidence","volume":"13","author":"Bhagwat","year":"2019","journal-title":"Drug Des. Devel Ther."},{"issue":"4","key":"10.1016\/j.phrs.2024.107431_bib110","article-title":"Real-world evidence of efficacy and safety of levonadifloxacin (Oral and IV) in the management of acute bacterial skin and skin structure infections (ABSSSI): findings of a retrospective, multi-center study","volume":"14","author":"Mehta","year":"2022","journal-title":"Cureus"},{"issue":"12","key":"10.1016\/j.phrs.2024.107431_bib111","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.jiac.2022.08.014","article-title":"Antimicrobial activity of ozenoxacin and other antimicrobials against Staphylococcus aureus strains isolated from clinical skin specimens in Japan in 2019 and 2020","volume":"28","author":"Kurokawa","year":"2022","journal-title":"J. Infect. Chemother."},{"issue":"3","key":"10.1016\/j.phrs.2024.107431_bib112","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/14787210.2019.1573671","article-title":"Ozenoxacin: a review of preclinical and clinical efficacy","volume":"17","author":"Vila","year":"2019","journal-title":"Expert Rev. Anti Infect. Ther."},{"issue":"10","key":"10.1016\/j.phrs.2024.107431_bib113","first-page":"1051","article-title":"Topical antibacterial agent for treatment of adult and pediatric patients with impetigo: pooled analysis of phase 3 clinical trials","volume":"17","author":"Hebert","year":"2018","journal-title":"J. Drugs Dermatol."},{"issue":"10","key":"10.1016\/j.phrs.2024.107431_bib114","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1039\/b808333a","article-title":"The aminocoumarins: biosynthesis and biology","volume":"26","author":"Heide","year":"2009","journal-title":"Nat. Prod. Rep."},{"issue":"5","key":"10.1016\/j.phrs.2024.107431_bib115","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1128\/AAC.48.5.1856-1864.2004","article-title":"Crystal structures of Escherichia coli topoisomerase IV ParE subunit (24 and 43 kilodaltons): a single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyrase","volume":"48","author":"Bellon","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"issue":"14","key":"10.1016\/j.phrs.2024.107431_bib116","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/S0960-894X(99)00329-7","article-title":"Synthesis and in vitro evaluation of novel highly potent coumarin inhibitors of gyrase B","volume":"9","author":"Laurin","year":"1999","journal-title":"Bioorg. Med Chem. Lett."},{"issue":"3","key":"10.1016\/j.phrs.2024.107431_bib117","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00253-011-3557-z","article-title":"Exploiting bacterial DNA gyrase as a drug target: current state and perspectives","volume":"92","author":"Collin","year":"2011","journal-title":"Appl. Microbiol Biotechnol."},{"key":"10.1016\/j.phrs.2024.107431_bib118","unstructured":"Determination That ALBAMYCIN (Novobiocin Sodium) Capsule, 250 Milligrams, Was Withdrawn From Sale for Reasons of Safety or Effectiveness. Federal Register\/Vol. 76, No. 12\/Wednesday, January 19, 2011\/Notices. Available at: \u3008https:\/\/www.govinfo.gov\/content\/pkg\/FR-2011-01-19\/pdf\/2011-1000.pdf\u3009."},{"issue":"2","key":"10.1016\/j.phrs.2024.107431_bib119","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0163-7258(03)00058-5","article-title":"Catalytic topoisomerase II inhibitors in cancer therapy","volume":"99","author":"Larsen","year":"2003","journal-title":"Pharm. Ther."},{"issue":"5","key":"10.1016\/j.phrs.2024.107431_bib120","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ijc.2910510519","article-title":"Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26)","volume":"51","author":"Rappa","year":"1992","journal-title":"Int J. Cancer"},{"issue":"2","key":"10.1016\/j.phrs.2024.107431_bib121","first-page":"127","article-title":"Novobiocin-induced VP-16 accumulation and MRP expression in human leukemia and ovarian carcinoma cells","volume":"15","author":"Rappa","year":"2000","journal-title":"Anticancer Drug Des."},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib122","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/ijc.11528","article-title":"Reversal of breast cancer resistance protein (BCRP\/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic","volume":"108","author":"Shiozawa","year":"2004","journal-title":"Int J. Cancer"},{"issue":"12","key":"10.1016\/j.phrs.2024.107431_bib123","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1002\/1097-0142(19910615)67:12<2969::AID-CNCR2820671205>3.0.CO;2-M","article-title":"Cisplatin and novobiocin in the treatment of non-small cell lung cancer. A Southwest Oncology Group study","volume":"67","author":"Ellis","year":"1991","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.phrs.2024.107431_bib124","doi-asserted-by":"crossref","DOI":"10.1002\/bip.23398","article-title":"Pyronaridine: An update of its pharmacological activities and mechanisms of action","volume":"112","author":"Bailly","year":"2021","journal-title":"Biopolymers"},{"issue":"3","key":"10.1016\/j.phrs.2024.107431_bib125","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1128\/AAC.37.3.403","article-title":"Structure-activity relationships and modes of action of 9-anilinoacridines against chloroquine-resistant Plasmodium falciparum in vitro","volume":"37","author":"Chavalitshewinkoon","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.phrs.2024.107431_bib126","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1006\/bbrc.2000.2305","article-title":"Cleavage of DNA induced by 9-anilinoacridine inhibitors of topoisomerase II in the malaria parasite Plasmodium falciparum","volume":"269","author":"Auparakkitanon","year":"2000","journal-title":"Biochem Biophys. Res Commun."},{"issue":"6","key":"10.1016\/j.phrs.2024.107431_bib127","article-title":"Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria","volume":"6","author":"Pryce","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib128","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2174\/2212697X08666210219101023","article-title":"The antimalarial drug pyronaridine inhibits topoisomerase ii in breast cancer cells and hinders tumor progression in vivo","volume":"8","author":"Villanueva","year":"2021","journal-title":"Clin. Cancer Drugs"},{"key":"10.1016\/j.phrs.2024.107431_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102711","article-title":"Old drug repurposing for neglected disease: Pyronaridine as a promising candidate for the treatment of Echinococcus granulosus infections","volume":"54","author":"Li","year":"2020","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.phrs.2024.107431_bib130","article-title":"DNA Topoisomerases","volume":"6","author":"Bush","year":"2015","journal-title":"EcoSal"},{"issue":"4","key":"10.1016\/j.phrs.2024.107431_bib131","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1383-5769(99)00028-8","article-title":"Gametocytocidal activity of pyronaridine and DNA topoisomerase II inhibitors against multidrug-resistant Plasmodium falciparum in vitro","volume":"48","author":"Chavalitshewinkoon-Petmitr","year":"2000","journal-title":"Parasitol. Int"},{"issue":"33","key":"10.1016\/j.phrs.2024.107431_bib132","doi-asserted-by":"crossref","first-page":"20313","DOI":"10.1074\/jbc.M115.639039","article-title":"Topoisomerase II from human malaria parasites: expression, purification, and selective inhibition","volume":"290","author":"Mudeppa","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.phrs.2024.107431_bib133","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/BF00273384","article-title":"Anthracycline analogs: the past, present, and future","volume":"18","author":"Weiss","year":"1986","journal-title":"Cancer Chemother. Pharm."},{"issue":"9","key":"10.1016\/j.phrs.2024.107431_bib134","first-page":"2819","article-title":"Pirarubicin (THP-adriamycin)]","volume":"15","author":"Tsukagoshi","year":"1988","journal-title":"Gan Kagaku Ryoho"},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib135","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2165\/00002512-199915010-00006","article-title":"Valrubicin","volume":"15","author":"Onrust","year":"1999","journal-title":"Drugs Aging"},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0305-7372(83)80029-2","article-title":"4'-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data","volume":"10","author":"Ganzina","year":"1983","journal-title":"Cancer Treat. Rev."},{"issue":"Suppl 5","key":"10.1016\/j.phrs.2024.107431_bib137","first-page":"374","article-title":"[Amrubicin]","volume":"60","author":"Shimizu","year":"2002","journal-title":"Nihon Rinsho"},{"issue":"2","key":"10.1016\/j.phrs.2024.107431_bib138","first-page":"152","article-title":"Idarubicin: an anthracycline antineoplastic agent","volume":"11","author":"Cersosimo","year":"1992","journal-title":"Clin. Pharm."},{"issue":"5","key":"10.1016\/j.phrs.2024.107431_bib139","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/1756287214541798","article-title":"Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer, including carcinoma in situ of the bladder","volume":"6","author":"Cookson","year":"2014","journal-title":"Ther. Adv. Urol."},{"issue":"2","key":"10.1016\/j.phrs.2024.107431_bib140","first-page":"123","article-title":"Aclarubicin: experimental and clinical experience","volume":"11","author":"R\u00f6thig","year":"1985","journal-title":"Drugs Exp. Clin. Res"},{"issue":"7","key":"10.1016\/j.phrs.2024.107431_bib141","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/j.1552-4604.1986.tb02942.x","article-title":"Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds","volume":"26","author":"Wadler","year":"1986","journal-title":"J. Clin. Pharm."},{"key":"10.1016\/j.phrs.2024.107431_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114145","article-title":"Podophyllotoxin and its derivatives: potential anticancer agents of natural origin in cancer chemotherapy","volume":"158","author":"Motyka","year":"2023","journal-title":"Biomed. Pharm."},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib143","first-page":"78","article-title":"Podophyllotoxin analogs: effects on DNA topoisomerase II, tubulin polymerization, human tumor KB cells, and their VP-16-resistant variants","volume":"36","author":"Liu","year":"1989","journal-title":"Mol. Pharm."},{"issue":"10","key":"10.1016\/j.phrs.2024.107431_bib144","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.phrs.2024.107431_bib145","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s40265-020-01281-4","article-title":"Trastuzumab deruxtecan: first approval","volume":"80","author":"Keam","year":"2020","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.phrs.2024.107431_bib146","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s40265-020-01337-5","article-title":"Sacituzumab govitecan: first approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.phrs.2024.107431_bib147","first-page":"1089","article-title":"[A novel antitumor agent, sobuzoxane (MST-16)]","volume":"21","author":"Tsukagoshi","year":"1994","journal-title":"Gan Kagaku Ryoho"},{"issue":"18","key":"10.1016\/j.phrs.2024.107431_bib148","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1091\/mbc.e14-04-0916","article-title":"How Taxol\/paclitaxel kills cancer cells","volume":"25","author":"Weaver","year":"2014","journal-title":"Mol. Biol. Cell"},{"issue":"4","key":"10.1016\/j.phrs.2024.107431_bib149","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/00001813-199904000-00008","article-title":"A unique paclitaxel-mediated modulation of the catalytic activity of topoisomerase IIalpha","volume":"10","author":"Dhawan","year":"1999","journal-title":"Anticancer Drugs"},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib150","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10557-016-6711-0","article-title":"Anthracycline chemotherapy and cardiotoxicity","volume":"31","author":"McGowan","year":"2017","journal-title":"Cardiovasc Drugs Ther."},{"issue":"12","key":"10.1016\/j.phrs.2024.107431_bib151","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1200\/JCO.1991.9.12.2148","article-title":"A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer","volume":"9","author":"Perez","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2024.107431_bib152","doi-asserted-by":"crossref","unstructured":"A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group 1 ( 103 Br. J. Haematol. , 1998, 031100\u2013109.","DOI":"10.1046\/j.1365-2141.1998.00948.x"},{"key":"10.1016\/j.phrs.2024.107431_bib153","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejca.2023.02.019","article-title":"Anthracycline-induced cardiotoxicity - are we about to clear this hurdle","volume":"185","author":"Dempke","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"21","key":"10.1016\/j.phrs.2024.107431_bib154","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.3390\/cancers14215436","article-title":"Pharmacogenetics of drug metabolism: the role of gene polymorphism in the regulation of doxorubicin safety and efficacy","volume":"14","author":"Bagdasaryan","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2024.107431_bib155","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1186\/1471-2407-14-842","article-title":"Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms","volume":"14","author":"Deng","year":"2014","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.phrs.2024.107431_bib156","article-title":"Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines","volume":"9","author":"de Baat","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.phrs.2024.107431_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2023.101205","article-title":"Doxorubicin and other anthracyclines in cancers: activity, chemoresistance and its overcoming","volume":"93","author":"Mattioli","year":"2023","journal-title":"Mol. Asp. Med"},{"issue":"5","key":"10.1016\/j.phrs.2024.107431_bib158","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005006.pub3","article-title":"Different anthracycline derivates for reducing cardiotoxicity in cancer patients","volume":"2010","author":"van Dalen","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"issue":"9","key":"10.1016\/j.phrs.2024.107431_bib159","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1200\/JCO.1989.7.9.1333","article-title":"A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer","volume":"7","author":"Slevin","year":"1989","journal-title":"J. Clin. Oncol."},{"issue":"1 Suppl","key":"10.1016\/j.phrs.2024.107431_bib160","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/1097-0142(19910101)67:1+<231::AID-CNCR2820671305>3.0.CO;2-E","article-title":"Current status of etoposide in the management of small cell lung cancer","volume":"67","author":"Johnson","year":"1991","journal-title":"Cancer"},{"issue":"1 Suppl","key":"10.1016\/j.phrs.2024.107431_bib161","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/1097-0142(19910101)67:1+<220::AID-CNCR2820671303>3.0.CO;2-O","article-title":"Etoposide therapy for testicular cancer","volume":"67","author":"Loehrer","year":"1991","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib162","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/BF03000484","article-title":"Etoposide and teniposide in the treatment of acute leukemia","volume":"7","author":"Bj\u00f6rkholm","year":"1990","journal-title":"Med Oncol. Tumor Pharm."},{"issue":"24","key":"10.1016\/j.phrs.2024.107431_bib163","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1056\/NEJM199112123252402","article-title":"Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia","volume":"325","author":"Pui","year":"1991","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2024.107431_bib164","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103607","article-title":"Diagnosis and treatment of therapy-related acute myeloid leukemia","volume":"171","author":"Strickland","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib165","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.1997.15.1.251","article-title":"Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy","volume":"15","author":"Rougier","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.phrs.2024.107431_bib166","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/oxfordjournals.annonc.a059107","article-title":"Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study","volume":"6","author":"Wagener","year":"1995","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.phrs.2024.107431_bib167","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00280-008-0839-y","article-title":"Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer","volume":"63","author":"Yi","year":"2009","journal-title":"Cancer Chemother. Pharm."},{"issue":"4","key":"10.1016\/j.phrs.2024.107431_bib168","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s41416-020-01055-5","article-title":"A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer","volume":"124","author":"Kang","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2024.107431_bib169","doi-asserted-by":"crossref","DOI":"10.1038\/srep18999","article-title":"Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients","volume":"6","author":"Horita","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2024.107431_bib170","doi-asserted-by":"crossref","DOI":"10.1038\/srep15437","article-title":"Topotecan for relapsed small-cell lung cancer: systematic review and meta-analysis of 1347 patients","volume":"5","author":"Horita","year":"2015","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib171","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1447-0756.2009.01101.x","article-title":"Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience","volume":"36","author":"Kim","year":"2010","journal-title":"J. Obstet. Gynaecol. Res"},{"issue":"6","key":"10.1016\/j.phrs.2024.107431_bib172","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/j.1525-1438.2007.01003.x","article-title":"Topotecan in cervical cancer","volume":"17","author":"Ackermann","year":"2007","journal-title":"Int J. Gynecol. Cancer"},{"issue":"7","key":"10.1016\/j.phrs.2024.107431_bib173","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"9","key":"10.1016\/j.phrs.2024.107431_bib174","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7168","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: real-life data from the temporary use authorization program in France","volume":"13","author":"Petit","year":"2024","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib175","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med"},{"issue":"3","key":"10.1016\/j.phrs.2024.107431_bib176","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N. Engl. J. Med"},{"issue":"25","key":"10.1016\/j.phrs.2024.107431_bib177","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2024.107431_bib178","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1001","article-title":"Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician\u2019s choice (TPC) in patients (Pts) with hormone receptor\u2013positive\/HER2-negative (HR+\/HER2-) advanced breast cancer","volume":"40","author":"Rugo","year":"2022","journal-title":"JCO"},{"issue":"16","key":"10.1016\/j.phrs.2024.107431_bib179","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med"},{"issue":"22","key":"10.1016\/j.phrs.2024.107431_bib180","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.phrs.2024.107431_bib181","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1200\/JCO.1988.6.6.976","article-title":"Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial","volume":"6","author":"Italian Multicentre Breast Study with Epirubicin","year":"1988","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib182","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/oxfordjournals.annonc.a057675","article-title":"Idarubicin and high-dose cytarabine in the treatment of refractory and relapsed acute lymphoblastic leukemia","volume":"1","author":"Giona","year":"1990","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.phrs.2024.107431_bib183","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1097\/JTO.0b013e318260de75","article-title":"Topotecan\/cisplatin compared with cisplatin\/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial","volume":"7","author":"Fink","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"10409","key":"10.1016\/j.phrs.2024.107431_bib184","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib185","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-68205-w","article-title":"Co-administration of H-ferritin-doxorubicin and Trastuzumab in neoadjuvant setting improves efficacy and prevents cardiotoxicity in HER2\u2009+\u2009murine breast cancer model","volume":"10","author":"Andreata","year":"2020","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.phrs.2024.107431_bib186","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1517\/13543784.2012.699038","article-title":"Vosaroxin: a novel antineoplastic quinolone","volume":"21","author":"Abbas","year":"2012","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.phrs.2024.107431_bib187","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.129016","article-title":"A first-in-class clinical G-quadruplex-targeting drug. The bench-to-bedside translation of the fluoroquinolone QQ58 to CX-5461 (Pidnarulex)","volume":"77","author":"Xu","year":"2022","journal-title":"Bioorg. Med Chem. Lett."},{"key":"10.1016\/j.phrs.2024.107431_bib188","doi-asserted-by":"crossref","first-page":"S1665","DOI":"10.1016\/j.annonc.2023.10.588","article-title":"509MO Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced\/metastatic (adv\/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01","volume":"Volume 34","author":"Ahn","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2024.107431_bib189","doi-asserted-by":"crossref","first-page":"S1264","DOI":"10.1016\/j.annonc.2023.10.015","article-title":"LBA11 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+\/HER2\u2013) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial","volume":"Volume 34","author":"Bardia","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2024.107431_bib190","unstructured":"AstraZeneca Press Release. Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer. Available at: \u3008https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2024\/fda-accepts-dato-dxd-bla-for-breast-cancer.html#!\u3009."},{"key":"10.1016\/j.phrs.2024.107431_bib191","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor\u2013mutated non\u2013small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.phrs.2024.107431_bib192","unstructured":"Daiichi-Sankyo Press Release. Ifinatamab Deruxtecan Continues to Demonstrate Durable Responses in Patients with Advanced Small Cell Lung Cancer in Early Trial. Available at: \u3008https:\/\/www.daiichisankyo.com\/files\/news\/pressrelease\/pdf\/202309\/20230910_E1.pdf\u3009."},{"key":"10.1016\/j.phrs.2024.107431_bib193","unstructured":"Daiichi-Sankyo Press Release. Raludotatug Deruxtecan Continues to Demonstrate Promising Clinical Activity in Patients with Advanced Ovarian Cancer in Early Trial. Available at: \u3008https:\/\/www.daiichisankyo.com\/files\/news\/pressrelease\/pdf\/202310\/20231022_E2.pdf\u3009."},{"issue":"3","key":"10.1016\/j.phrs.2024.107431_bib194","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1158\/1535-7163.MCT-23-0287","article-title":"Raludotatug deruxtecan, a CDH6-targeting antibody-drug conjugate with a DNA topoisomerase I inhibitor DXd, is efficacious in human ovarian and kidney cancer models","volume":"23","author":"Suzuki","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2024.107431_bib195","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122886","article-title":"Recent advances in SN-38 drug delivery system","volume":"637","author":"Yang","year":"2023","journal-title":"Int J. Pharm."},{"issue":"11","key":"10.1016\/j.phrs.2024.107431_bib196","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1158\/1535-7163.MCT-22-0217","article-title":"PLX038: A long-acting topoisomerase I inhibitor with robust antitumor activity in ATM-deficient tumors and potent synergy with PARP inhibitors","volume":"21","author":"Thomas","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib197","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00280-019-03987-z","article-title":"PLX038: a PEGylated prodrug of SN-38 independent of UGT1A1 activity","volume":"85","author":"Fontaine","year":"2020","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.phrs.2024.107431_bib198","unstructured":"National Cancer Institute. FDA grants orphan drug designation to indotecan for the treatment of glioma. Available at: \u3008https:\/\/ccr.cancer.gov\/news\/article\/fda-grants-orphan-drug-designation-to-indotecan-for-the-treatment-of-glioma\u3009."},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib199","article-title":"Combined inhibition of topoisomerase I and poly(ADP-ribose) polymerase: a synergistic therapeutic strategy for glioblastoma with phosphatase and tensin homolog deficiency","volume":"5","author":"Kim","year":"2023","journal-title":"Neurooncol Adv."},{"issue":"20","key":"10.1016\/j.phrs.2024.107431_bib200","doi-asserted-by":"crossref","first-page":"6206","DOI":"10.1158\/1078-0432.CCR-19-0419","article-title":"The indenoisoquinoline TOP1 inhibitors selectively target homologous recombination-deficient and schlafen 11-positive cancer cells and synergize with olaparib","volume":"25","author":"Marzi","year":"2019","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.phrs.2024.107431_bib201","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1200\/JCO.2023.41.16_suppl.3022","article-title":"Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas","volume":"41","author":"Ko","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.phrs.2024.107431_bib202","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1200\/JCO.2017.35.15_suppl.2558","article-title":"Phase I study of indenoisoquinolines LMP776 in adults with relapsed solid tumors and lymphomas","volume":"35","author":"O'Sullivan Coyne","year":"2017","journal-title":"JCO"},{"issue":"6","key":"10.1016\/j.phrs.2024.107431_bib203","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s10637-016-0388-x","article-title":"Comparative effects of doxorubicin and a doxorubicin analog, 13-deoxy, 5-iminodoxorubicin (GPX-150), on human topoisomerase II\u03b2 activity and cardiac function in a chronic rabbit model","volume":"34","author":"Frank","year":"2016","journal-title":"Invest N. Drugs"},{"issue":"6","key":"10.1016\/j.phrs.2024.107431_bib204","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1002\/cam4.2136","article-title":"A phase II clinical study of 13-deoxy, 5-iminodoxorubicin (GPX-150) with metastatic and unresectable soft tissue sarcoma","volume":"8","author":"Van Tine","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.phrs.2024.107431_bib205","unstructured":"Monopar Therapeutics Press Release. Monopar Provides Encouraging Camsirubicin Clinical Data Update. Available at: \u3008https:\/\/ir.monopartx.com\/press-releases\/detail\/75\/monoparprovides-encouraging-camsirubicin-clinical-data\u3009."},{"issue":"2","key":"10.1016\/j.phrs.2024.107431_bib206","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1182\/blood.V88.2.633.bloodjournal882633","article-title":"The novel anthracycline annamycin is not affected by P-glycoprotein- related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines","volume":"88","author":"Consoli","year":"1996","journal-title":"Blood"},{"issue":"2A","key":"10.1016\/j.phrs.2024.107431_bib207","first-page":"1277","article-title":"Comparison of annamycin to adriamycin in cardiac and MDR tumor cell systems","volume":"19","author":"Kolonias","year":"1999","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib208","first-page":"613","article-title":"Results of a phase I Study of Liposomal Annamycin for Treatment of R\/R AML Patients","volume":"6","author":"Gil","year":"2023","journal-title":"Br. J. Cancer Res"},{"key":"10.1016\/j.phrs.2024.107431_bib209","unstructured":"Z. Muzyczenko, S. Silberman, S. Hsu, D. Picker. A Randomized, Controlled Trial Of Berubicin, A Novel Topoisomerase II Inhibitor, After First-Line Therapy For Glioblastoma Multiforme (GBM): Updated Results. 2023 SNO\/ASCO CNS Cancer Conference. Available at: \u3008https:\/\/assets.cnspharma.com\/production\/publications\/Berubicin-SNO-ASCO-Poster-2023.pdf?dm=1717154550\u3009."},{"issue":"9","key":"10.1016\/j.phrs.2024.107431_bib210","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1001\/jamaoncol.2015.3101","article-title":"First-line aldoxorubicin vs doxorubicin in metastatic or locally advanced unresectable soft-tissue sarcoma: a phase 2b randomized clinical trial","volume":"1","author":"Chawla","year":"2015","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.phrs.2024.107431_bib211","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10637-014-0183-5","article-title":"Pharmacokinetic study of aldoxorubicin in patients with solid tumors","volume":"33","author":"Mita","year":"2015","journal-title":"Invest N. Drugs"},{"issue":"10","key":"10.1016\/j.phrs.2024.107431_bib212","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1073\/pnas.85.10.3585","article-title":"Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol","volume":"85","author":"Olson","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"33","key":"10.1016\/j.phrs.2024.107431_bib213","doi-asserted-by":"crossref","first-page":"15851","DOI":"10.1016\/S0021-9258(18)47666-1","article-title":"The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps. A correlative study of cardiac muscle with isolated membrane fractions","volume":"262","author":"Boucek","year":"1987","journal-title":"J. Biol. Chem."},{"issue":"20","key":"10.1016\/j.phrs.2024.107431_bib214","doi-asserted-by":"crossref","first-page":"11252","DOI":"10.1002\/anie.202101938","article-title":"Improving bioavailability of hydrophobic prodrugs through supramolecular nanocarriers based on recombinant proteins for osteosarcoma treatment","volume":"60","author":"Wang","year":"2021","journal-title":"Angew. Chem. Int Ed. Engl."},{"issue":"4","key":"10.1016\/j.phrs.2024.107431_bib215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010186","article-title":"Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II","volume":"5","author":"Hawtin","year":"2010","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.phrs.2024.107431_bib216","doi-asserted-by":"crossref","first-page":"606","DOI":"10.18632\/oncotarget.195","article-title":"Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks","volume":"1","author":"Hawtin","year":"2010","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib217","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00280-008-0850-3","article-title":"Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models","volume":"64","author":"Hoch","year":"2009","journal-title":"Cancer Chemother. Pharm."},{"issue":"6","key":"10.1016\/j.phrs.2024.107431_bib218","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/bjh.13214","article-title":"REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia","volume":"168","author":"Stuart","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.phrs.2024.107431_bib219","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s10637-017-0428-1","article-title":"Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II","volume":"35","author":"Nijenhuis","year":"2017","journal-title":"Invest N. Drugs"},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib220","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1038\/s41467-022-31199-2","article-title":"Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies","volume":"13","author":"Hilton","year":"2022","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.phrs.2024.107431_bib221","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1073\/pnas.1921649117","article-title":"The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning","volume":"117","author":"Bruno","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib222","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1038\/s41467-021-26640-x","article-title":"The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma","volume":"12","author":"Pan","year":"2021","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.phrs.2024.107431_bib223","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41416-020-01158-z","article-title":"The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer","volume":"124","author":"Yan","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2024.107431_bib224","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2018.07.025","article-title":"Copper-CX-5461: A novel liposomal formulation for a small molecule rRNA synthesis inhibitor","volume":"286","author":"Leung","year":"2018","journal-title":"J. Control Release"},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib225","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41588-023-01602-9","article-title":"The chemotherapeutic drug CX-5461 is a potent mutagen in cultured human cells","volume":"56","author":"Koh","year":"2024","journal-title":"Nat. Genet"},{"issue":"6","key":"10.1016\/j.phrs.2024.107431_bib226","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1021\/acsinfecdis.0c00021","article-title":"Zoliflodacin: An Oral Spiropyrimidinetrione Antibiotic for the Treatment of Neisseria gonorrheae, Including Multi-Drug-Resistant Isolates","volume":"6","author":"Bradford","year":"2020","journal-title":"ACS Infect. Dis."},{"issue":"5","key":"10.1016\/j.phrs.2024.107431_bib227","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/jac\/dkad060","article-title":"Gepotidacin: a novel, oral, 'first-in-class' triazaacenaphthylene antibiotic for the treatment of uncomplicated urinary tract infections and urogenital gonorrhoea","volume":"78","author":"Watkins","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.phrs.2024.107431_bib228","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/JEP.S242959","article-title":"Investigational TReatment Agents for Recurrent Clostridioides Difficile Infection (rCDI)","volume":"12","author":"Kullar","year":"2020","journal-title":"J. Exp. Pharm."},{"key":"10.1016\/j.phrs.2024.107431_bib229","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.659845","article-title":"Macrocycle-antibiotic hybrids: a path to clinical candidates","volume":"9","author":"Surur","year":"2021","journal-title":"Front Chem."},{"issue":"11","key":"10.1016\/j.phrs.2024.107431_bib230","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1021\/acs.jmedchem.9b01738","article-title":"Two decades of successful SAR-grounded stories of the novel bacterial topoisomerase inhibitors (NBTIs)","volume":"63","author":"Kolari\u010d","year":"2020","journal-title":"J. Med Chem."},{"issue":"7309","key":"10.1016\/j.phrs.2024.107431_bib231","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nature09197","article-title":"Type IIA topoisomerase inhibition by a new class of antibacterial agents","volume":"466","author":"Bax","year":"2010","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.phrs.2024.107431_bib232","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1128\/AAC.00247-08","article-title":"Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors","volume":"52","author":"Miller","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"issue":"34","key":"10.1016\/j.phrs.2024.107431_bib233","doi-asserted-by":"crossref","first-page":"20984","DOI":"10.1074\/jbc.M115.663534","article-title":"Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914","volume":"290","author":"Kern","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2024.107431_bib234","unstructured":"The Global Antibiotic Research & Development Partnership. Positive results announced in largest pivotal phase 3 trial of a first-in-class oral antibiotic to treat uncomplicated gonorrhoea. Available at: \u3008https:\/\/gardp.org\/positive-results-announced-in-largest-pivotal-phase-3-trial-of-a-first-in-class-oral-antibiotic-to-treat-uncomplicated-gonorrhoea\/\u3009."},{"issue":"19","key":"10.1016\/j.phrs.2024.107431_bib235","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1706988","article-title":"Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea","volume":"379","author":"Taylor","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"4","key":"10.1016\/j.phrs.2024.107431_bib236","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/cid\/ciy145","article-title":"Gepotidacin for the treatment of uncomplicated urogenital gonorrhea: a phase 2, randomized, dose-ranging, single-oral dose evaluation","volume":"67","author":"Taylor","year":"2018","journal-title":"Clin. Infect. Dis."},{"issue":"10428","key":"10.1016\/j.phrs.2024.107431_bib237","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(23)02196-7","article-title":"Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials","volume":"403","author":"Wagenlehner","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib238","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41598-023-49943-z","article-title":"Gonococcal resistance to zoliflodacin could emerge via transformation from commensal Neisseria species. an in-vitro transformation study","volume":"14","author":"Abdellati","year":"2024","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.phrs.2024.107431_bib239","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ijantimicag.2014.03.016","article-title":"Ecological impact of MCB3837 on the normal human microbiota","volume":"44","author":"Rashid","year":"2014","journal-title":"Int J. Antimicrob. Agents"},{"issue":"23","key":"10.1016\/j.phrs.2024.107431_bib240","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1016\/j.bmcl.2003.07.021","article-title":"Novel oxazolidinone-quinolone hybrid antimicrobials","volume":"13","author":"Gordeev","year":"2003","journal-title":"Bioorg. Med Chem. Lett."},{"issue":"3","key":"10.1016\/j.phrs.2024.107431_bib241","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02077-16","article-title":"In vitro activities of MCB3681 and eight comparators against clostridium difficile isolates with known ribotypes and diverse geographical spread","volume":"61","author":"Freeman","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.phrs.2024.107431_bib242","unstructured":"Tennor Therapeutics Pipeline. Available at: \u3008https:\/\/www.tennorx.com\/en\/pipeline.html#section01\u3009."},{"key":"10.1016\/j.phrs.2024.107431_bib243","article-title":"In-vitro characterisation of a novel antimicrobial agent, TNP-2092, against Helicobacter pylori clinical isolates","volume":"148","author":"Wang","year":"2018","journal-title":"Swiss Med Wkly"},{"issue":"3","key":"10.1016\/j.phrs.2024.107431_bib244","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2020.115040","article-title":"In vitro activity of TNP-2092 against periprosthetic joint infection-associated staphylococci","volume":"97","author":"Fisher","year":"2020","journal-title":"Diagn. Microbiol Infect. Dis."},{"key":"10.1016\/j.phrs.2024.107431_bib245","article-title":"The efficacy and safety of intra-articular dual-acting antibacterial agent (TNP-2092) for implant infection-associated MRSA","author":"Dai","year":"2023","journal-title":"J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.phrs.2024.107431_bib246","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1021\/acsinfecdis.9b00374","article-title":"Evaluation of a dual-acting antibacterial agent, TNP-2092, on gut microbiota and potential application in the treatment of gastrointestinal and liver disorders","volume":"6","author":"Yuan","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.phrs.2024.107431_bib247","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.659845","article-title":"Macrocycle-antibiotic hybrids: a path to clinical candidates","volume":"9","author":"Surur","year":"2021","journal-title":"Front Chem."},{"issue":"4","key":"10.1016\/j.phrs.2024.107431_bib248","article-title":"In Vitro and In Vivo Antibacterial Activities of a Novel Quinolone Compound, OPS-2071, against Clostridioides difficile [published correction appears in Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0233821. doi: 10.1128\/aac.02338-21]","volume":"65","author":"Oka","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"10.1016\/j.phrs.2024.107431_bib249","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1093\/jac\/dkac308","article-title":"In vitro antibacterial activity of OPS-2071 against Gram-positive and Gram-negative enteropathogenic bacteria","volume":"77","author":"Oka","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"issue":"8","key":"10.1016\/j.phrs.2024.107431_bib250","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1007\/s10620-021-07237-2","article-title":"Antibacterial and immunosuppressive effects of OPS-2071, a candidate therapy for inflammatory bowel disease","volume":"67","author":"Sato","year":"2022","journal-title":"Dig. Dis. Sci."},{"issue":"34","key":"10.1016\/j.phrs.2024.107431_bib251","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2218483120","article-title":"Identification and characterization of topoisomerase III beta poisons","volume":"120","author":"Wang","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"12","key":"10.1016\/j.phrs.2024.107431_bib252","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1021\/acs.orglett.0c01456","article-title":"Discovery, biosynthesis, and heterologous production of loonamycin, a potent anticancer indolocarbazole alkaloid","volume":"22","author":"Yang","year":"2020","journal-title":"Org. Lett."},{"issue":"7","key":"10.1016\/j.phrs.2024.107431_bib253","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.bmcl.2016.02.034","article-title":"Inhibition of human DNA topoisomerase II\u03b1 by two novel ellipticine derivatives","volume":"26","author":"Vann","year":"2016","journal-title":"Bioorg. Med Chem. Lett."},{"issue":"20","key":"10.1016\/j.phrs.2024.107431_bib254","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.3390\/molecules27206958","article-title":"Transcriptomics and proteomics characterizing the anticancer mechanisms of natural rebeccamycin analog loonamycin in breast cancer cells","volume":"27","author":"Sun","year":"2022","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.phrs.2024.107431_bib255","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/tcr.201402100","article-title":"Boron-based drug design","volume":"15","author":"Ban","year":"2015","journal-title":"Chem. Rec."},{"issue":"8","key":"10.1016\/j.phrs.2024.107431_bib256","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1158\/1535-7163.MCT-19-1064","article-title":"The Indenoisoquinoline LMP517: a novel antitumor agent targeting both TOP1 and TOP2","volume":"19","author":"Marzi","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2024.107431_bib257","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.837373","article-title":"A Novel Copper(II) Indenoisoquinoline Complex Inhibits Topoisomerase I, Induces G2 Phase Arrest, and Autophagy in Three Adenocarcinomas","volume":"12","author":"Molinaro","year":"2022","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib258","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1021\/acschembio.5b00669","article-title":"New simocyclinones: surprising evolutionary and biosynthetic insights","volume":"11","author":"Bilyk","year":"2016","journal-title":"ACS Chem. Biol."},{"issue":"3","key":"10.1016\/j.phrs.2024.107431_bib259","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1128\/AAC.49.3.1093-1100.2005","article-title":"Simocyclinone D8, an inhibitor of DNA gyrase with a novel mode of action","volume":"49","author":"Flatman","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"10.1016\/j.phrs.2024.107431_bib260","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1038\/s41557-024-01516-x","article-title":"Discovery of isoquinoline sulfonamides as allosteric gyrase inhibitors with activity against fluoroquinolone-resistant bacteria","volume":"16","author":"Bakker","year":"2024","journal-title":"Nat. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib261","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1038\/s41598-024-54252-0","article-title":"Targeting yeast topoisomerase II by imidazo and triazoloacridinone derivatives resulting in their antifungal activity","volume":"14","author":"Rz\u0105d","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2024.107431_bib262","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.antiviral.2018.06.014","article-title":"Genistein inhibits African swine fever virus replication in vitro by disrupting viral DNA synthesis","volume":"156","author":"Arabyan","year":"2018","journal-title":"Antivir. Res"},{"issue":"3","key":"10.1016\/j.phrs.2024.107431_bib263","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.neuroscience.2008.07.024","article-title":"DNA topoisomerase I inhibitors ameliorate seizure-like behaviors and paralysis in a Drosophila model of epilepsy","volume":"156","author":"Song","year":"2008","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.phrs.2024.107431_bib264","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/carcin\/bgq260","article-title":"Paradoxical effects of ethoxidine, a topoisomerase I inhibitor, in the cellular processes leading to angiogenesis on endothelial cells","volume":"32","author":"Clere","year":"2011","journal-title":"Carcinogenesis"},{"issue":"4","key":"10.1016\/j.phrs.2024.107431_bib265","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3390\/molecules22040627","article-title":"Pro-angiogenic effects of low dose ethoxidine in a murine model of ischemic hindlimb: correlation between ethoxidine levels and increased activation of the nitric oxide pathway","volume":"22","author":"Clere","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2024.107431_bib266","unstructured":"Exelixis Press Release. Helsinn to Discontinue Becatecarin Trial Program. Available at: \u3008https:\/\/ir.exelixis.com\/news-releases\/news-release-details\/helsinn-discontinue-becatecarin-trial-program\u3009."},{"issue":"9","key":"10.1016\/j.phrs.2024.107431_bib267","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1007\/s00253-019-09741-y","article-title":"The antitumor antibiotic rebeccamycin-challenges and advanced approaches in production processes","volume":"103","author":"Pommerehne","year":"2019","journal-title":"Appl. Microbiol Biotechnol."},{"key":"10.1016\/j.phrs.2024.107431_bib268","unstructured":"Biospace. Novexel Discontinues Development of NXL 101. Available at: \u3008https:\/\/www.biospace.com\/novexel-discontinues-development-of-nxl-101\u3009."},{"issue":"5","key":"10.1016\/j.phrs.2024.107431_bib269","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1099\/jmm.0.000475","article-title":"Mechanisms of quinolone action and resistance: where do we stand","volume":"66","author":"Correia","year":"2017","journal-title":"J. Med Microbiol"},{"issue":"4","key":"10.1016\/j.phrs.2024.107431_bib270","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00007-19","article-title":"Transferable Mechanisms of Quinolone Resistance from 1998 Onward","volume":"32","author":"Ruiz","year":"2019","journal-title":"Clin. Microbiol Rev."},{"key":"10.1016\/j.phrs.2024.107431_bib271","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2023.101205","article-title":"Doxorubicin and other anthracyclines in cancers: activity, chemoresistance and its overcoming","volume":"93","author":"Mattioli","year":"2023","journal-title":"Mol. Asp. Med"},{"issue":"8","key":"10.1016\/j.phrs.2024.107431_bib272","doi-asserted-by":"crossref","first-page":"7233","DOI":"10.3390\/ijms24087233","article-title":"Resistance to TOP-1 inhibitors: good old drugs still can surprise us","volume":"24","author":"Kumar","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.phrs.2024.107431_bib273","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s43018-021-00203-x","article-title":"A First-in-class Polymerase Theta Inhibitor Selectively Targets Homologous-recombination-deficient Tumors","volume":"2","author":"Zhou","year":"2021","journal-title":"Nat. Cancer"},{"issue":"2","key":"10.1016\/j.phrs.2024.107431_bib274","doi-asserted-by":"crossref","first-page":"697","DOI":"10.21873\/anticanres.15528","article-title":"CHFR-promoter-methylation status is predictive of response to irinotecan-based systemic chemotherapy in advanced colorectal cancer","volume":"42","author":"Hagiwara","year":"2022","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1016\/j.phrs.2024.107431_bib275","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00408-020-00333-6","article-title":"High Systemic Immune-Inflammation Index (SII) Represents an Unfavorable Prognostic Factor for Small Cell Lung Cancer Treated with Etoposide and Platinum-Based Chemotherapy","volume":"198","author":"Wang","year":"2020","journal-title":"Lung"},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib276","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s12253-017-0312-5","article-title":"Overexpression of TIMP-1 and Sensitivity to Topoisomerase Inhibitors in Glioblastoma Cell Lines","volume":"25","author":"Aaberg-Jessen","year":"2019","journal-title":"Pathol. Oncol. Res"},{"issue":"7","key":"10.1016\/j.phrs.2024.107431_bib277","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1158\/1535-7163.MCT-21-1000","article-title":"TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor","volume":"21","author":"Jo","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"7546","key":"10.1016\/j.phrs.2024.107431_bib278","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature14122","article-title":"EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors [published correction appears in Nature. 2018 Nov;563(7732):E27. doi: 10.1038\/s41586-018-0580-6]","volume":"520","author":"Fillmore","year":"2015","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib279","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1186\/s12885-019-5788-9","article-title":"Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene","volume":"19","author":"K\u00fcmler","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.phrs.2024.107431_bib280","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115303","article-title":"Design, synthesis and biological evaluation of dual Topo II\/HDAC inhibitors bearing pyrimido[5,4-b]indole and pyrazolo[3,4-d]pyrimidine motifs","volume":"252","author":"Zhao","year":"2023","journal-title":"Eur. J. Med Chem."},{"issue":"1","key":"10.1016\/j.phrs.2024.107431_bib281","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11060-018-2862-0","article-title":"Tumor-related epilepsy: epidemiology, pathogenesis and management","volume":"139","author":"Chen","year":"2018","journal-title":"J. Neurooncol"},{"issue":"15","key":"10.1016\/j.phrs.2024.107431_bib282","doi-asserted-by":"crossref","first-page":"6062","DOI":"10.1021\/acs.jcim.4c00472","article-title":"Insights into the DNA and RNA Interactions of Human Topoisomerase III Beta Using Molecular Dynamics Simulations","volume":"64","author":"Mamun","year":"2024","journal-title":"J. Chem. Inf. Model"},{"key":"10.1016\/j.phrs.2024.107431_bib283","unstructured":"Data Bridge Market Research. Global Quinolones Market \u2013 Industry Trends and Forecast to 2030. Available at: \u3008https:\/\/www.databridgemarketresearch.com\/reports\/global-quinolones-market\u3009."},{"key":"10.1016\/j.phrs.2024.107431_bib284","unstructured":"The Business Research Company. Quinolones Global Market Report 2024. Available at: \u3008https:\/\/www.thebusinessresearchcompany.com\/report\/quinolones-global-market-report\u3009."},{"key":"10.1016\/j.phrs.2024.107431_bib285","unstructured":"Allied Market Research. Quinolones Market Size, Share, Competitive Landscape and Trend Analysis Report by Product Type, by Application and by End User: Global Opportunity Analysis and Industry Forecast, 2023-2032. Available at: \u3008https:\/\/www.alliedmarketresearch.com\/quinolones-market-A14826\u3009."},{"key":"10.1016\/j.phrs.2024.107431_bib286","unstructured":"Data Bridge Market Research. Global Anthracyclines Market \u2013 Industry Trends and Forecast to 2030. Available at: \u3008https:\/\/www.databridgemarketresearch.com\/reports\/global-anthracyclines-market\u3009."},{"key":"10.1016\/j.phrs.2024.107431_bib287","unstructured":"The Business Research Company. Anthracycline Global Market Report 2024. Available at: \u3008https:\/\/www.thebusinessresearchcompany.com\/report\/anthracycline-global-market-report\u3009."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824003761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824003761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T19:56:24Z","timestamp":1731009384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661824003761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":287,"alternative-id":["S1043661824003761"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107431","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent developments of topoisomerase inhibitors: Clinical trials, emerging indications, novel molecules and global sales","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107431","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107431"}}